Ascelia Pharma AB (SE:ACE)
:ACE
Want to see SE:ACE full AI Analyst Report?
ACE Stock Chart & Stats
kr3.17
-kr0.11(-3.47%)
At close: 4:00 PM EST
kr3.17
-kr0.11(-3.47%)
Day’s Range― - ―
52-Week Rangekr2.53 - kr5.23
Previous CloseN/A
Volume171.87K
Average Volume (3M)1.75M
Market Cap
kr382.58M
Enterprise Valuekr358.83M
Total Cash (Recent Filing)kr33.89M
Total Debt (Recent Filing)kr689.00K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding133,535,460
10 Day Avg. Volume1,883,755
30 Day Avg. Volume1,753,338
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.26
Revenue Forecast (FY)kr87.22M
Bulls Say, Bears Say
Bulls Say
Focused Lead Asset (Orviglance)Orviglance targets a specific diagnostic niche—MRI contrast for patients contraindicated for gadolinium. A focused, clinically differentiated asset can enable clearer regulatory paths, targeted commercial positioning and partnership opportunities, creating a durable value driver if clinical and regulatory milestones are met.
Very Low Financial LeverageNear-zero reported debt reduces interest obligations and financial distress risk, preserving strategic flexibility. Low leverage makes it easier to raise non-debt capital, seek partnerships, or endure trial timelines without looming debt maturities, supporting longer-term viability while development progresses.
Improving Cash Burn TrendAn improving burn rate versus prior peak years signals better cost control or trial efficiency, which lengthens runway and reduces near-term refinancing pressure. Sustained improvement can materially raise the odds of reaching key development inflection points with less dilution.
Bears Say
No Revenue And Structural LossesAs a development-stage biotech with no product sales, the company relies on external funding and milestone events for progression. Large, recurring losses consume equity and create ongoing financing dependency, limiting long-term independence and increasing execution risk if capital markets or partner options tighten.
Weak Cash Generation / High BurnConsistently negative operating and free cash flow indicate the company is not self-funding its operations. High burn necessitates frequent capital raises or partnerships, raising dilution and execution risk; persistent cash outflows constrain ability to expand trials or commercial preparations without external capital.
Eroding Equity And Negative ROEDeclining equity and deeply negative ROE reflect ongoing capital consumption from losses, weakening the balance sheet over time. This trend reduces strategic optionality, increases vulnerability to adverse events, and raises the probability of dilutive financing or restructuring if profitability remains elusive.
Ascelia Pharma AB News
ACE FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr2.53 and its highest was kr5.23 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is kr382.58M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 71 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on May 12, 2026. The company reported -kr0.129 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.129.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 133,535,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -kr0.129 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.372%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in SE:ACE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―